Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

BMC Cancer

Table 1 Protocols selected as the most common choice

	Protocol/trial (% of responding clinicians selecting protocol/trial as most common choice)
	Adults with Ph − disease		Adults with Ph + disease
France	GRAALL 2014	50	ALL GRAALLPHAG06/EWALL-PH–01	35
Germany	GMALL 08 2013	65	GMALL 08 2013	65
Italy^a	GIMEMA LAL1913	42	GIMEMA LAL1811	25
Spain	PETHEMA LAL-AR/2011	57	PETHEMA LAL PH–2008	59
UK	UK ALL 14	70	UK ALL 14	68

^aUse of a range of GIMEMA protocols was reported for Italy, reflecting different populations (GIMEMA LAL1913, GIMEMA LAL1104, and GIMEMA LAL1308 for Ph − disease; GIMEMA LAL1811 and GIMEMA LAL1408 for Ph + disease)
ALL, acute lymphoblastic leukemia; Ph, Philadelphia chromosome translocation

ISSN: 1471-2407